Table 1.
Formulation parameters and physicochemical properties of eGFP mRNA LNPs.
| Formulation | Composition | Size (nm) | Zeta potential (mV) | PDI | Encapsulation efficiency (%) | Cell viability (%)* | |
|---|---|---|---|---|---|---|---|
| 1 | DOTAP | 40% | 102 ± 11.3 | 16.5 ± 3.2 | 0.37 ± 0.09 | 81.6 ± 4.9 | 87.6 ± 4.0 |
| DLin-MC3-DMA | 20% | ||||||
| DPPC | 10% | ||||||
| Cholesterol | 28.50% | ||||||
| PEG-DSPE | 1.50% | ||||||
| 2 | DOTAP | 40% | 37.8 ± 6.4 | 47.9 ± 5.5 | 0.30 ± 0.07 | 85.6 ± 3.6 | 84.0 ± 3.5 |
| DLin-MC3-DMA | 10% | ||||||
| DPPC | 10% | ||||||
| Cholesterol | 37% | ||||||
| PEG-DSPE | 3% | ||||||
| 3 | DOTAP | 40% | 122 ± 13.8 | 19.8 ± 3.6 | 0.39 ± 0.11 | 78.0 ± 6.6 | 89.0 ± 1.8 |
| DLin-MC3-DMA | 10% | ||||||
| DPPC | 10% | ||||||
| Cholesterol | 28.50% | ||||||
| PEG-DSPE | 1.50% | ||||||
| 4 | DOTAP | 50% | 43.8 ± 8.6 | 27.4 ± 2.2 | 0.26 ± 0.7 | 87.0 ± 7.6 | 80.7 ± 1.8 |
| DLin-MC3-DMA | 25% | ||||||
| DPPC | 5% | ||||||
| Cholesterol | 18.50% | ||||||
| PEG-DSPE | 1.50% | ||||||
| 5 | DOTAP | 40% | 34.2 ± 0.8 | 11.5 ± 2.4 | 0.29 ± 0.08 | 85.5 ± 5.3 | 83.8 ± 1.8 |
| DLin-MC3-DMA | 25% | ||||||
| DPPC | 10% | ||||||
| Cholesterol | 23.50% | ||||||
| PEG-DSPE | 1.50% | ||||||
*
Viability derived from cell experiments at 1 μg/mL